earnings
confidence high
sentiment neutral
materiality 0.60
Nuwellis Q3 revenue $2.2M, down 6% YoY, up 29% sequentially; operating loss widens to $2.7M
Nuwellis, Inc.
2025-Q3 EPS reported
-$39.51
revenue$5,846,000
- Total revenue $2.2M, down 6% YoY but up 29% sequentially; pro-forma revenue grew ~7% YoY excluding one-time items.
- Gross margin 65.2% (down from 70% YoY); operating loss $2.7M vs $1.5M last year.
- Cash $3.1M at quarter end, debt-free; raised $1.9M via ATM facility.
- Launched new 24-hour circuit and dual-lumen catheter; first hospital-based outpatient therapies under new CMS code.
- Pediatric Vivian system accelerated with NIH funding; manufacturing transition to KDI Precision initiated.